1. Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
   Ruth Plummer et al, 2007, Clinical Cancer Research CrossRef
2. Molecular Mode of Action of TRAIL Receptor Agonists—Common Principles and Their Translational Exploitation
   null Wajant, 2019, Cancers CrossRef
3. Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Pathway and Its Therapeutic Implications
   Elisabeth G.E. de Vries et al, 2006, Clinical Cancer Research CrossRef
4. Enhancement of Lexatumumab-Induced Apoptosis in Human Solid Cancer Cells by Cisplatin in Caspase-Dependent Manner
   Xiu-Xian Wu et al, 2009, Clinical Cancer Research CrossRef
5. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region
   Karthikeyan Kandasamy et al, 2008, Molecular Cancer Therapeutics CrossRef
6. Prognostic Value of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer
   Stephan Macher-Goeppinger et al, 2009, Clinical Cancer Research CrossRef
7. Low-Dose 12-O-Tetradecanoylphorbol-13-Acetate Enhances Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis in Prostate Cancer Cells
   Xiaoping Zhang et al, 2007, Clinical Cancer Research CrossRef
8. Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox
   null Lim et al, 2019, Cancers CrossRef
9. Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma
   Chunjing Wu et al, 2021, International Journal of Molecular Sciences CrossRef